Clinical Trials for Waldenstrom Macroglobulinemia

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

NCT ID: NCT05640102

This clinical trial is studying the effectiveness and safety of a medication called zanubrutinib for patients with Waldenström Macroglobulinemia (WM), a type of blood cancer. The study aims to gath...

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCT ID: NCT04840602

This clinical trial is testing a new treatment for patients with Waldenstrom's macroglobulinemia, a type of blood cancer. Researchers want to see if combining two medications, venetoclax and rituxi...

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

NCT ID: NCT00923507

This clinical trial is studying different blood cancers, including Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Lymphoplasmacytic Lym...

Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia

NCT ID: NCT04893564

This clinical trial is studying how the presence of circulating tumoral DNA (ctDNA) in the blood can help predict the risk of disease progression or relapse in patients with Waldenström Macroglobul...

Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia

NCT ID: NCT04898647

This clinical trial is studying a condition called hyperviscosity syndrome (HVS) in patients with Waldenström Macroglobulinemia (WM), a type of blood cancer. HVS occurs when there is a high level o...

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT ID: NCT01804686

This clinical trial is focused on studying the long-term safety and effectiveness of a medication called ibrutinib for patients with various types of blood cancers, including chronic lymphocytic le...

Loncastuximab Tesirine in WM

NCT ID: NCT05190705

This clinical trial is exploring the safety and effectiveness of a new treatment called loncastuximab tesirine for patients with Waldenström Macroglobulinemia (WM), a type of blood cancer. The stud...

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

NCT ID: NCT05734495

This clinical trial is studying a new combination treatment for Waldenström Macroglobulinemia (WM), a type of blood cancer. The researchers want to see how safe and effective two medications, pirto...

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

NCT ID: NCT06340737

This clinical trial is studying a new treatment called CD22 CAR T-cell therapy for adults with certain types of blood cancers known as B cell lymphomas. These cancers include follicular lymphoma, m...

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT ID: NCT05602363

This clinical trial is studying a new oral medication called AS-1763 (docirbrutinib) for patients with certain types of blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocyti...

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

NCT ID: NCT05065554

This clinical trial is exploring a new treatment approach for patients with certain blood conditions that can cause nerve damage, specifically Immunoglobulin M monoclonal gammopathy of undetermined...

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT ID: NCT02269592

This clinical trial is studying different types of blood cancers, including conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS), Chronic Lymphocytic Leukemia (CLL), and early ...

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT ID: NCT05952037

This clinical trial is studying a new treatment called sonrotoclax for people with Waldenström's Macroglobulinemia (WM), a type of blood cancer. The trial is looking at how safe and effective sonro...

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

NCT ID: NCT05099471

This clinical trial is studying a new treatment approach for Waldenström's macroglobulinemia (WM), a type of blood cancer. The researchers want to see if combining two medications, Venetoclax and R...

Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia

NCT ID: NCT06547866

This clinical trial is studying a new treatment combination of two medications, zanubrutinib and BGB-11417, for patients with Waldenström macroglobulinemia (WM), a type of blood cancer. The trial i...

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

NCT ID: NCT06151730

The HALT Study is looking at how to manage high blood pressure in patients with certain types of B-cell cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma, who are starting trea...

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

NCT ID: NCT06860880

This clinical trial, titled "Combating Cancer-Related Fatigue: A Personalized Supportive Care Program," is designed to help patients with certain types of indolent lymphomas, including chronic lymp...

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT ID: NCT04488354

Epcoritamab in Previously Treated WM

NCT ID: NCT06510491

This clinical trial is investigating a new treatment called epcoritamab for patients with Waldenstrom Macroglobulinemia (WM), a type of cancer that affects the blood and immune system. The study ai...

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

NCT ID: NCT06561347

This clinical trial is testing a combination of three medications—zanubrutinib, bendamustine, and rituximab—to see how well they work in treating patients with Waldenström macroglobulinemia (WM), a...